…patient who is clinically unwell must be managed as an emergency even at a lower temperature. Suspect neutropenia in anyone who has received cytotoxic chemotherapy…

…including pexelizumab, losmapimod and darapladib, failed to demonstrate clinical benefit in the settings studied. Clinical application and patient populations The evidence for anti inflammatory treatment…

…Presently, this treatment is confined to well equipped centers and is generally reserved for meticulously selected cases. Extracorporeal Life Support (ECLS) encompasses several extracorporeal systems…

…Adults with blood pressure ≥140/90 mmHg should receive both lifestyle and antihypertensive drug therapy. For grade 1 hypertension, pharmacological treatment has demonstrated cardiovascular benefit…

…and prevent its interaction with the hepatic LDL receptor. They lower LDL C by approximately 50–60%, including in patients receiving background statin therapy and…

…two treatment groups with respect to either the primary or secondary outcomes. Primary outcome events occurred in 49% of patients in the milrinone group and…

…near the ventricular cavity, and it may to some extent receive oxygen from the blood in the ventricular cavity. The right bundle branch then runs…

…major active metabolite. Both the parent drug and its metabolite accumulate extensively in various tissues, including the liver, lung, fat, and skin, with myocardial concentrations…

…examination Patients referred for echocardiography should receive information regarding the conduction of the examination. Some patient engagement is required to obtain all views and the…

…patient for 24 hours (including ECG monitoring). In all other situations, the underlying condition should be targeted and, if necessary, bradycardia should be treated (treatment…